journal cover

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

PloS One

Jul 12, 2014

Zineb BelcaidMichael Lim

Abstract

Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a poor prognosis. Cytotoxic T lymphocyte antigen -4 (CTLA-4) blocking antibodies have demonstrated an ability to generate robust antitumor immune responses against a variety of solid tumors. 4-1...read more

Mentioned in this Paper

Monoclonal Antibodies
Tumor Cells, Uncertain Whether Benign or Malignant
Immune Response
Monoclonal antibodies, antineoplastic
Gp100 Antigen
Tumor Immunity
T-Lymphocyte
TNFRSF9 gene
C57BL/6 Mouse
Melanoma, Experimental
6
5
115
Paper Details
References
  • References32
  • Citations44
1234
  • References32
  • Citations44
12345

Similar Papers Found In These Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Downstream Antiviral T Cell

Lymphoid Neoplasms

Lymphoid neoplasms are derived from cells that frequently have features that recapitulate stages of normal b-, t-, and nk-cell differentiation and function. Lymphoid neoplasms include the following morphologic types: follicular center cell, lymphoblast (lymphocytic), immunoblast, plasma cell, and large granular lymphocyte (lgl). Here is the latest research on lymphoid neoplasms.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Non-Small Cell Lung Cancer Recurrence

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is a tumor that develops from astrocytes and oligodendrocytes. Here is the latest research on mechanisms that underlie GBM and associated therapeutic approaches.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Immunologic Surveillance

Immunological surveillance occurs when T-cells detect and destroy virally infected or neoplastically transformed cells in the body. Discover the latest research on immunologic surveillance here.

Radiosensitizers

A radiosensitizer is an agent that makes tumor cells more sensitive to radiation therapy. It is sometimes also known as a radiation sensitizer or radio-enhancer. Discover the latest research on radiosensitizers here.

Immunomodulating Agents

Immunomodulating agents are substances that stimulate or suppresse the immune system and may help the body combat againsts cancer, infection, or other diseases. Discover the latest research on immunomodulating agents here.

Drug-Induced Diseases

Drug-induced diseases (DID) also called as iatrogenic diseases. Most of these DIDs are largely preventable, if strict vigilance and proper periodic clinical and diagnostic monitoring are undertaken

Skin Cutaneous Melanoma

Cutaneous melanoma is a cancer of the pigment-producing cells known as melanocytes. While it has a 98 percent five-year survival rate when caught early, thousands of deaths are attributed to this cancer each year. Here is the latest research.

Follicular T Helper Cells

Follicular t helper cells are an important subset of helper t-cells which help to the formation of germinal centers and b-cells differentiation. Discover the latest research on follicular t helper cells here.

Killing Mechanisms

Cytolytic t lymphocytes exert two main specific molecular killing mechanisms against target cells, namely (i) they can synthesize and release soluble cytolytic factors, and (ii) they can express effector molecules that act as ligands of receptors expressed by target cells on the cell surface. Here is the latest research on killing mechanisms.

T cells: Costimulatory Receptors

T cell activation requires engagement of both the T cell receptor and a co-stimulatory molecule. Lack of a co-stimulatory signal can result in T cell anergy, deletion, or immune tolerance. Find the latest research on T cell co-stimulatory receptors here.

Glioma Cells

Killer Cells

Natural killer cells express inhibitory receptors specific for mhc class i proteins and stimulatory receptors with diverse specificities. Here is the latest research on natural killer cells.

Immunogenetics of CNS Tumors

Central nervous system (CNS) tumors have a unique tumor immune microenvironment, where immune cells can play a role in disease progression and resistance to therapy. Studying the immunogenetics of these cells can uncover mechanisms underlying their role in CNS tumors. Here is the latest research.

Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by genetic defects in SMN1 gene, which encodes survival motor neuron 1 (SMN1) protein. SMA is characterized by loss of lower motor neurons and progressive muscle wasting. Here is the latest research on this rare condition.

© 2020 Meta ULC. All rights reserved

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

PloS One

Jul 12, 2014

Zineb BelcaidMichael Lim

PMID: 25013914

DOI: 10.1371/journal.pone.0101764

Abstract

Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a poor prognosis. Cytotoxic T lymphocyte antigen -4 (CTLA-4) blocking antibodies have demonstrated an ability to generate robust antitumor immune responses against a variety of solid tumors. 4-1...read more

Mentioned in this Paper

Monoclonal Antibodies
Tumor Cells, Uncertain Whether Benign or Malignant
Immune Response
Monoclonal antibodies, antineoplastic
Gp100 Antigen
Tumor Immunity
T-Lymphocyte
TNFRSF9 gene
C57BL/6 Mouse
Melanoma, Experimental
6
5
115

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References32
  • Citations44
1234
  • References32
  • Citations44
12345
/papers/focal-radiation-therapy-combined-with-4-1bb/25013914